News

Explore the emotional and physical challenges of chronic hand eczema through a patient's journey and expert insights on empathetic care and innovative treatments.

Lakshi Aldredge, MSN, ANP-BC, DCNP, discussed key symptoms of CHE, the function of the JAK-STAT pathway, and key data from the DELTA trials evaluating delgocitinib cream at the Horizons in Advanced Practice meeting.

Celldex is launching a phase 3 trial for barzolvolimab, targeting cold urticaria and symptomatic dermographism, offering hope for effective treatment options.

Discover the efficacy and safety of topical roflumilast 0.3% for psoriasis, highlighting its rapid results and potential for sensitive skin areas.

AI could revolutionize vitiligo management with enhanced diagnostics, automated tracking, and personalized treatment forecasting, improving patient care and outcomes.

Dermatology Times highlights 2025's innovations in dermatology, featuring new therapies, expert insights, and a look ahead to 2026 advancements.

John Barbieri, MD, MBA, outlines how missing reviewer identification, unclear step-therapy requirements, and limited engagement during appeals contribute to delays, inefficiencies, and potential clinical harm for patients.

PolarityBio advances SkinTE for diabetic foot ulcers, aiming for a breakthrough in chronic wound treatment with promising trial results announced soon.

Kymera Therapeutics reveals promising phase 1b results for KT-621, an oral STAT6 degrader, showing significant effects in moderate to severe atopic dermatitis.

Discover how hotel shampoos, conditioners, and body washes contribute to allergic contact dermatitis, revealing significant regional differences in allergen prevalence.

The first treatment follows Zevaskyn’s FDA approval as the first autologous, gene-modified cellular sheet designed to address RDEB wounds.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about clascoterone 5% for hair growth improvements, dermatology's role in lung cancer toxicities, IPV in female psoriasis patients, and more.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

A study reveals high rates of intimate partner violence among women with psoriasis, linking it to poorer quality of life and increased PTSD symptoms.

At a Dermatology Times Case-Based Roundtable event, Joe Gorelick, MSN, FNP-C, reviewed real-world strategies for hidradenitis suppurativa, highlighting growing preference for bimekizumab based on its dual IL-17A/IL-17F inhibition.

Discover the latest insights on laser and energy-based treatments for rosacea, highlighting the effectiveness of radiofrequency microneedling and combination therapies.

Experts explore the integration of AI in atopic dermatitis management, highlighting benefits, risks, and the need for cautious implementation in patient care.

New study reveals how microneedle radiofrequency technology effectively addresses postpartum abdominal skin laxity, enhancing skin elasticity and patient satisfaction.

Selected pieces will be featured in Dermatology Times’ year-end and early-2026 coverage.

InnoCare Pharma has initiated a global trial for soficitinib, targeting prurigo nodularis, aiming to enhance treatment options for this chronic skin condition.

Omar Noor, MD, outlines the complex phenotypes, variable presentations, and functional burdens of chronic hand eczema and explains why a broader JAK-targeted strategy may offer therapeutic advantages.

Alpha-9 Oncology's A9-3408 trial targets MC1R in advanced melanoma, offering a novel radiotherapeutic approach beyond traditional treatments.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of December.

Cosmo Pharmaceuticals reveals promising phase 3 results for clascoterone 5% solution, showing significant hair growth improvement in alopecia.

Tori Spelling and Stella McDermott share their journey with eczema, promoting the Free to Be Me campaign and discussing innovative treatments like roflumilast.

At the Horizons in Advanced Practice meeting, Omar Noor, MD, led NP and PA attendees through 3 complex cases of atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

Arash Mostaghimi, MD, MPH, FAAD, and experts discuss evolving treatment standards for alopecia areata, focusing on JAK inhibitors, patient-centered care, and future therapeutic innovations.